EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Adjuvant donafenib for hepatocellular carcinoma patients at high-risk of recurrence after radical resection: a real-world experience

Shenyu Zhang iD, Guibin Yang, Ruipeng Song, Wei Wang, Fanzheng Meng, Dalong Yin, Jiabei Wang, Shugeng Zhang, Wei Cai, Yao Liu, Dayong Luo, Jizhou Wang iD und 1 weitere

Therapeutic Advances in Medical Oncology · 2024-01 · 16

DOI: 10.1177/17588359241258394 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Therapeutic Advances in Medical Oncology, online erschienen am 12.06.2024. Verfasst von Shenyu Zhang und 12 weiteren Autor:innen. Beteiligte Einrichtung: Division of Life Sciences and Medicine, Department of Hepatobiliary Surgery, Centre for Leading Medicine and Advanced Technologies of IHM, The First …. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: National Key Research and Development Program of China, National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Adjuvant therapy is used to reduce the risk of hepatocellular carcinoma (HCC) recurrence and improve patient prognosis. Exploration of treatment strategies that are both efficacious and safe has been extensively performed in the recent years. Although donafenib has demonstrated good efficacy in the treatment of advanced HCC, its use as adjuvant therapy in HCC has not been reported.

Objectives

To investigate the efficacy and safety of postoperative adjuvant donafenib treatment in patients with HCC at high-risk of recurrence.

Design

Retrospective study.

Methods

A total of 196 patients with HCC at high-risk of recurrence were included in this study. Of these, 49 received adjuvant donafenib treatment, while 147 did not. Survival outcomes and incidence of adverse events (AEs) in the donafenib-treated group were compared. Inverse probability of treatment weighting (IPTW) method was used.

Results

The median follow-up duration was 21.8 months [interquartile range (IQR) 17.2–27.1]. Before IPTW, the donafenib-treated group exhibited a significantly higher 1-year recurrence-free survival (RFS) rate (83.7% versus 66.7%, p = 0.023) than the control group. Contrarily, no significant difference was observed in the 1-year overall survival (OS) rates between the two groups (97.8% versus 91.8%, p = 0.120). After IPTW, the 1-year RFS and OS rates (86.6% versus 64.8%, p = 0.004; 97.9% versus 89.5%, p = 0.043, respectively) were higher than those in the control group. Multivariate analysis revealed that postoperative adjuvant donafenib treatment was an independent protective factor for RFS. The median duration of adjuvant donafenib treatment was 13.6 (IQR, 10.7–18.1) months, with 44 patients (89.8%) experienced AEs, primarily grade 1–2 AEs.

Conclusion

Postoperative adjuvant donafenib treatment effectively reduced early recurrence among patients with HCC at high-risk of recurrence, while exhibiting favorable safety and tolerability profile. However, these findings warrant further investigation.

Schlagwörter

Stichwörter der Autor:innen

adverse eventsdonafenibefficacyhepatocellular carcinomapostoperative adjuvant therapysafety

Autor:innen und Institutionen

  • Division of Life Sciences and Medicine, Department of Hepatobiliary Surgery, Centre for Leading Medicine and Advanced Technologies of IHM, The First Affiliated Hospital of USTC, University of Science and Technology of C…
  • Department of Hepatic-Biliary-Pancreatic Surgery, No. 2 People's Hospital of Fuyang City, Fuyang, Anhui, China.
  • Division of Life Sciences and Medicine, Department of Medical Oncology, The First Affiliated Hospital of USTC, University of Science and Technology of China, Hefei, Anhui, China.
  • Department of Hepatic-Biliary-Pancreatic Surgery, No. 2 People's Hospital of Fuyang City, 1088 Yinghe West Road, Yingzhou District, Fuyang, Anhui 236015, China.
  • Anhui Provincial Clinical Research Center for Hepatobiliary Diseases, Hefei, Anhui, China.
  • Anhui Province Key Laboratory of Hepatopancreatobiliary Surgery, Hefei, Anhui, China.

ORCID-Profile: Shenyu Zhang, Jizhou Wang, Lianxin Liu

Förderung

  • National Key Research and Development Program of China
  • National Natural Science Foundation of China

Zitieren

APA

Zhang, S., Yang, G., Song, R., Wang, W., Meng, F., Yin, D., Wang, J., Zhang, S., Cai, W., Liu, Y., Luo, D., Wang, J., & Liu, L. (2024). Adjuvant donafenib for hepatocellular carcinoma patients at high-risk of recurrence after radical resection: a real-world experience. Therapeutic Advances in Medical Oncology, 16. https://doi.org/10.1177/17588359241258394

Vancouver

Zhang S, Yang G, Song R, Wang W, Meng F, Yin D, et al. Adjuvant donafenib for hepatocellular carcinoma patients at high-risk of recurrence after radical resection: a real-world experience. Therapeutic Advances in Medical Oncology. 2024;16. doi:10.1177/17588359241258394

BibTeX
@article{Zhang2024,
  author = {Zhang, Shenyu and Yang, Guibin and Song, Ruipeng and Wang, Wei and Meng, Fanzheng and Yin, Dalong and Wang, Jiabei and Zhang, Shugeng and Cai, Wei and Liu, Yao and Luo, Dayong and Wang, Jizhou and Liu, Lianxin},
  title = {Adjuvant donafenib for hepatocellular carcinoma patients at high-risk of recurrence after radical resection: a real-world experience},
  journal = {Therapeutic Advances in Medical Oncology},
  year = {2024},
  volume = {16},
  doi = {10.1177/17588359241258394}
}
Kostenlos starten →